[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"🔥 $LLY vs $NVO The Battle of the Obesity Kings $NVO is busy spending on acquisitions while $LLY just dropped another monster quarter 💪 Eli Lilly Q3: 💰 Revenue: $17.6B (vs $16.07B est) +54% YoY 📈 EPS (Non-GAAP): $XXXX (vs $XXXX est) 🧾 Gross Margin: XXXX% 🚀 FY25 Guidance Raised: Revenue: $63.063.5B (vs $61.63B est) EPS: $23.00$23.70 (vs $XXXXX est) CEO David Ricks: Lilly delivered another strong quarter driven by demand for our incretin portfolio. Were expanding globally scaling capacity and building the future of metabolic health. $LLY is executing flawlessly scaling innovating and"
X Link @rahuls61193 2025-10-30T17:57Z XXX followers, XX engagements
"$LLY Eli Lilly Q325 Earnings Highlights 🔹 Revenue: $17.60B (Est. $16.07B) 🟢; UP +54% YoY 🔹 EPS (Non-GAAP): $XXXX (Est. $5.89) 🟢 🔹 Gross Margin: XXXX% FY25 Guidance 🔹 Revenue: $63.0B$63.5B (Est. $61.63B) 🟢 🔹 EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) 🟢 🔹 Adj. Gross Margin: XX% 🔹 Performance Margin: 45%46% (Non-GAAP) Segment 🔹 Mounjaro: $6.52B; UP +109% YoY 🔹 Zepbound: $3.59B; UP +185% YoY 🔹 Verzenio: $1.47B; UP +7% YoY Other Metrics 🔹 U.S. Revenue: $11.30B; UP +45% YoY 🔹 OUS Revenue: $6.30B; UP +74% YoY CEO Commentary 🔸 Lilly delivered another strong quarter with XX% revenue"
X Link @dominic_pirrone 2025-10-30T14:34Z 5483 followers, XXX engagements
"$LLY Eli Lilly reports Q3 EPS $XXXX consensus $XXXX -- Q3 revenue $17.6B consensus $16.07B. -- Raises FY25 EPS view to $23.00-$23.70 from $21.75-$23.00 consensus $XXXXX. -- Raises FY25 revenue view to $63B-$63.5B from $60B-$62B consensus $61.63B"
X Link @CorleoneDon77 2025-10-30T11:17Z 6449 followers, XXX engagements
"$NVO busy spending money on acquisitions. Value = unclear. Meanwhile $LLY with another great quarter. Maybe I should be investing in $LLY instead of $NVO Eli Lilly's Q3 numbers: - Revenue: $17.60B (Est. $16.07B) 🟢+54% YoY - EPS (Non-GAAP): $XXXX (Est. $5.89) 🟢 - Gross Margin: 82.9%🟢 FY25 Guidance raised -- - Revenue: $63.0B$63.5B (Est. $61.63B) 🟢 - EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) 🟢 $LLY CEO David Ricks: Lilly delivered another strong quarter with XX% revenue growth year-over-year driven by continued demand for our incretin portfolio". " We advanced Orforglipron through four"
X Link @TacticzH 2025-10-30T11:11Z 29.3K followers, 28.5K engagements